A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer

BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is dysregulated in small-cell lung cancer (SCLC) and everolimus is an oral mTOR inhibitor. METHODS: This phase-1b study assessed everolimus safety at the levels of 2.5, 5, or 10 mg once daily in combination with paclitaxel (175 mg m(−2)) o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Sun, J M, Kim, J R, Do, I G, Lee, S Y, Lee, J, Choi, Y L, Ahn, J S, Ahn, M J, Park, K
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2013
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776982/
https://ncbi.nlm.nih.gov/pubmed/23963141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.467
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi